25 April 2024
25 April 2024
The decision was supported by three controlled clinical trials that showed the efficacy of Pivya in treating UTIs.
The approval is based on the Phase III EMBARK trial.
Lutathera is approved by the US FDA to treat patients aged 12 years and older with rare gastroenteropancreatic neuroendocrine cancer.
The company highlighted the successful market launch of LEQEMBI, with global in-market sales reaching approximately $19m.
Speakers discuss how SMEs can attract capital after a rise in investment activity in Q1 2024 compared to the last quarter of 2023.
At the Swiss Biotech Day conference, panelists at an investment talk discussed the current state of the Swiss investment landscape.
The agreement includes the transfer of responsibilities for the ongoing ReSPECT Phase III clinical trial.
The investment is part of Merck's broader €1.5bn commitment to the Darmstadt site by 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
